Cell-bound complement activation products as lupus biomarkers: diagnosis, monitoring and stratification

References

• Illei GG, Tackey E, Lapteva L, et al. Biomarkers in systemic lupus erythematosus. I. General overview and their applicability. Arthritis Rheum. 2004;50:1709–1720.
   PubMed Web of Science ®Google Scholar
• Illei GG, Tackey E, Lapteva L, et al. Biomarkers in systemic lupus erythematosus. II. Markers of disease activity. Arthritis Rheum. 2004;50:1709–1720.
   PubMed Web of Science ®Google Scholar
• Merrill JT, Buyon JP. The role of biomarkers in the assessment of lupus. Best Pract Res Clin Rheumatol. 2005;19:709–726.
   PubMed Web of Science ®Google Scholar
• Ahearn JM, Liu CC, Manzi S. Curr Treat Options in Rheum. 2015;1:1.
   Google Scholar
• Satoh M, Chan EK, Rose KM, et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum. 2012;64:2319–2327.
   PubMed Web of Science ®Google Scholar
• Narain S, Richards H, Satoh, et al. Diagnostic accuracy for lupus and other systemic autoimmune diseases in the community setting. Arch Intern Med. 2004;164:2435–2441.
   PubMed Web of Science ®Google Scholar
• Liu CC, Ahearn JM, Manzi S. Complement as a source of biomarkers in systemic lupus erythematosus: past, present, and future. Curr Rheum Rep. 2004;6:85–88.
   PubMedGoogle Scholar
• Liu CC, Manzi M, Danchenko N, et al. New advances in measurement of complement activation: lessons of systemic lupus erythematosus. Curr Rheum Rep. 2004;6:375–381.
   PubMedGoogle Scholar
• Calano SJ, Shih PB, Liu CC, et al. Cell-bound complement activation products (CB-CAPs) as a source of lupus biomarkers. Adv Exp Med Biol. 2006;586:381–390.
   PubMed Web of Science ®Google Scholar
• Ramsey-Goldman R, Li J, Dervieux T, et al. Cell-bound complement activation products in SLE. Lupus Science & Medicine. 2017;4:e000236.
   PubMed Web of Science ®Google Scholar
• Sturfelt G, Jonasson L, Sjoholm AG. Sequential studies of complement activation in systemic lupus erythematosus. Scand J Rheumatol. 1985;14:184–196.
   PubMed Web of Science ®Google Scholar
• Hopkins P, Belmont HM, Buyon JP, et al. Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum. 1988;31:632–641.
   PubMed Web of Science ®Google Scholar
• Wild G, Watkins J, Ward AM, et al. C4a anaphylatoxin levels as an indicator of disease activity in systemic lupus erythematosus. Clin Exp Immunol. 1990;80:167–170.
   PubMed Web of Science ®Google Scholar
• Porcel JM, Ordi J, Castro-Salomo A, et al. The value of complement activation products in the assessment of systemic lupus erythematosus flares. Clin Immunol Immunopathol. 1995;74:283–288.
   PubMedGoogle Scholar
• Manzi S, Rairie JE, Carpenter AB, et al. Sensitivity and specificity of plasma and urine split products as indicators of lupus disease activity. Arthritis Rheum. 1996;39:1178–1188.
   PubMed Web of Science ®Google Scholar
• Buyon JP, Tamerius J, Belmont HM, et al. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus: comparisonof the use of complement split products and conventional measurements of complement. Arthritis Rheum. 1992;35:1028–1037.
   PubMed Web of Science ®Google Scholar
• Manzi S, Navratil JS, Ruffing MJ, et al. Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus. Arthritis Rheum. 2004;50:3596–3604.
   PubMed Web of Science ®Google Scholar
• Navratil JS, Manzi S, Kao AH, et al. Platelet C4d is highly specific for systemic lupus erythematosus. Arthritis Rheum. 2006;54:670–674.
   PubMed Web of Science ®Google Scholar
• Liu CC, Kao AH, Hawkins DM, et al. Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus. Clin Transl Sci. 2009;2:300–308.
   PubMed Web of Science ®Google Scholar
• Kalunian KC, Chatham WW, Massarotti EM, et al. Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus. Arthritis Rheum. 2012;64:4040–4047.
   PubMed Web of Science ®Google Scholar
• Ahearn JM, Liu CC and Manzi S. The lupus biomarker odyssey: one experience. Methods Mol Biol. 2014;1134:17–35.
   PubMedGoogle Scholar
• Dervieux T, Conklin J, Ligayon JA, et al. Validation of a multi-analyte panel with cell-bound complement activation products for systemic lupus erythematosus. Immunol Methods. 2017 Jul;446:54–59. Epub 2017 Apr 5. DOI:10.1016/j.jim.2017.04.001
   PubMed Web of Science ®Google Scholar
• Putterman C, Furie R, Ramsey-Goldman R, et al. Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double stranded DNA and standard complement measurements. Lupus Science & Medicine. 2014;1:8:e000056.
   Google Scholar
• Wallace DJ, Silverman SL, Conklin J, et al. Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products. Lupus Science & Medicine. 2016;3:7:e000127.
   Google Scholar
• Wallace DJ, Massarotti E, Ramsey-Goldman R, et al. Cell bound complement activation products distinguish systemic lupus erythematosus from other diseases among patients with high antinuclear antibody titers and normal complement [abstract]. Arthritis Rheumatol. 2017;69(suppl 10).
   Google Scholar
• Kao AH, Navratil JS, Ruffing MJ, et al. Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus. Arthritis Rheum. 2010;62:837–844.
   PubMed Web of Science ®Google Scholar
• Liu CC, Manzi S, Kao AH, et al. Cell-bound complement biomarkers for systemic lupus erythematosus: from benchtop to bedside. Rheum Dis Clin N Am. 2010;36:161–172.
   PubMed Web of Science ®Google Scholar
• Liu CC, Manzi S, Kao AH, et al. Reticulocytes bearing C4d as biomarkers of disease activity for systemic lupus erythematosus. Arthritis Rheum. 2005;52:3087–3099.
   PubMed Web of Science ®Google Scholar
• Yang DH, Chang DM, Lai JH, et al. Usefulness of erythrocyte-bound C4d as a biomarker to predict disease activity in patients with systemic lupus erythematosus. Rheumatology. 2009;48:1083–1087.
   PubMed Web of Science ®Google Scholar
• Mora C, Medina-Rosas J, Santos AM, et al. Associations of the levels of C4d-bearing reticulocytes and high-avidity anti-dsDNA antibodies with disease activity in systemic lupus erythematosus. J Rheumatol. 2016;43:1657–1664.
   PubMed Web of Science ®Google Scholar
• Buyon J, Furie R, Putterman C, et al. Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical; improvement in systemic lupus erythematosus. Lupus Science & Medicine. 2016;3:7:e000165.
   Google Scholar
• Arriens C, Narain S, Saxena A, et al. Abnormalities in complement system are related to disease severity in systemic lupus erythematosus (SLE) [abstract]. Arthritis Rheumatol. 2017;69(suppl10).
   Google Scholar
• Kao AH, McBurney CA, Sattar A, et al. Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus. Transl Stroke Res. 2014;5:510–518.
   PubMed Web of Science ®Google Scholar
• Lood C, Eriksson S, Gullstrand B, et al. Increased C1q, C4 and C3 deposition on platelets in patients with systemic lupus erythematosus-a possible link to venous thrombosis? Lupus. 2012;21:1423–1432.
   PubMed Web of Science ®Google Scholar
• Hui-Yuen J, Barken D, Conklin J, et al. Cell-bound complement activation products correlate with disease activity in childhood-onset systemic lupus erythematosus [abstract]. Arthritis Rheumatol. 2017;69(suppl 4).
   Google Scholar
• Gartshteyn Y, Hui-Yuen J, Okado M, et al. Cell-bound complement activation products as markers of disease flares in childhood onset systemic lupus erythematosus [abstract]. Arthritis Rheumatol. 2017;69(suppl 10).
   Google Scholar
• Liu CC, Ahearn J, Tang AX, et al. Human C4 gene copy number influences cell-bound complement activation product (CB-CAP) C4d in systemic lupus erythematosus [abstract]. Arthritis Rheumatol. 2017;69(suppl 10).
   Google Scholar
• Iorio F, Knijnenburg TA, Vis DJ, et al. A landscape of pharmacogenomic interactions in cancer. Cell. 2016;166:740–754.
   PubMed Web of Science ®Google Scholar